Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 14/20 | 0.60 |
| ▸ | CDK8 | P49336 | 2/20 | 0.56 |
| ▸ | CDK7 | P50613 | 1/20 | 0.56 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 4/20 | 0.55 |
| ▸ | BRAF | P15056 | 3/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.55 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17360239 | 0.89 | NTRK1 (0.70) | NTRK1CDK8CDK7CDK6KDR | |
| SCHEMBL17360441 | 0.88 | NTRK1 (0.62) | NTRK1CDK8CDK7CDK6KDR | |
| SCHEMBL17360292 | 0.87 | NTRK1 (0.77) | NTRK1CDK8CDK7CDK6KDR | |
| SCHEMBL17360200 | 0.87 | NTRK1 (0.70) | NTRK1KDRPDGFRB | |
| SCHEMBL17360114 | 0.86 | NTRK1 (0.78) | NTRK1KDRPDGFRB | |
| SCHEMBL15989451 | 0.86 | NTRK1 (0.63) | NTRK1KDRPDGFRB | |
| SCHEMBL17360133 | 0.86 | NTRK1 (0.80) | NTRK1 | |
| SCHEMBL17360196 | 0.85 | NTRK1 (0.81) | NTRK1 | |
| SCHEMBL15989452 | 0.84 | NTRK1 (0.61) | NTRK1CDK8CDK7CDK6KDR | |
| SCHEMBL17360229 | 0.84 | NTRK1 (0.65) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10765676-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-08 | — | — | US | disclosed |
| US-20190231777-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-01 | — | — | US | disclosed |
| US-10300060-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20180256573-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-9993479-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-12 | — | — | US | disclosed |
| US-20170340634-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-30 | — | — | US | disclosed |
| US-9763943-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-09-19 | — | — | US | disclosed |
| US-20170027939-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-9498453-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9463192-B2 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20160280684-A1 | TRK-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20160000783-A1 | Trk-INHIBITING COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2960234-A1 | Trk-INHIBITING COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300060-B2 | Trk-inhibiting compound | LTK, ROR1, TRPV1 | NTRK1 33/4885CDK8 1285/4885CDK7 723/4885 |
| US-20180256573-A1 | Trk-INHIBITING COMPOUND | LTK, ROR1, TRPV1 | NTRK1 33/4885CDK8 1285/4885CDK7 723/4885 |
| US-20160280684-A1 | TRK-INHIBITING COMPOUND | LTK, ROR1, TRPV1 | NTRK1 33/4885CDK8 1285/4885CDK7 723/4885 |
| US-20160000783-A1 | Trk-INHIBITING COMPOUND | LTK, ROR1, TRPV1 | NTRK1 33/4885CDK8 1285/4885CDK7 723/4885 |
| US-20190231777-A1 | Trk-INHIBITING COMPOUND | LTK, ROR1, TRPV1 | NTRK1 33/4885CDK8 1285/4885CDK7 723/4885 |
| US-20170340634-A1 | Trk-INHIBITING COMPOUND | LTK, ROR1, TRPV1 | NTRK1 33/4885CDK8 1285/4885CDK7 723/4885 |
| US-10765676-B2 | Trk-inhibiting compound | LTK, ROR1, TRPV1 | NTRK1 33/4885CDK8 1285/4885CDK7 723/4885 |
| US-20170027939-A1 | Trk-INHIBITING COMPOUND | LTK, ROR1, TRPV1 | NTRK1 33/4885CDK8 1285/4885CDK7 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.